Top

Published in:

01-04-2020 | Acute Promyelocytic Leukemia | Original Article

Chemogenomics analysis of drug targets for the treatment of acute promyelocytic leukemia

Authors: Si Chen, Xiang Li, Shifan Ma, Xinrui Xing, Xiaobo Wang, Zhenyu Zhu

Published in: Annals of Hematology | Issue 4/2020

Abstract

The main challenges in treating acute promyelocytic leukemia (APL) are currently early mortality, relapse, refractory disease after induction therapy, and drug resistance to ATRA and ATO. In this study, a computational chemogenomics approach was used to identify new molecular targets and drugs for APL treatment. The transcriptional profiles induced by APL were compared with those induced by genetic or chemical perturbations. The genes that can reverse the transcriptional profiles induced by APL when perturbed were considered to be potential therapeutic targets for APL. Drugs targeting these genes or proteins are predicted to be able to treat APL if they can reverse the APL-induced transcriptional profiles. To improve the target identification accuracy of the above correlation method, we plotted the functional protein association networks of the predicted targets by STRING. The results determined PML, RARA, SPI1, HDAC3, CEBPA, NPM1, ABL1, BCR, PTEN, FOS, PDGFRB, FGFR1, NUP98, AFF1, and MEIS1 to be top candidates. Interestingly, the functions of PML, RARA, HDAC3, CEBPA, NPM1, ABL, and BCR in APL have been previously reported in the literature. This is the first chemogenomics analysis predicting potential APL drug targets, and the findings could be used to guide the design of new drugs targeting refractory and recurrent APL.

Available only for authorised users

Coombs CC, Tavakkoli M, Tallman MS (2015) Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J 5:e304. https://doi.org/10.1038/bcj.2015.25 CrossRefPubMedPubMedCentral

Breccia M, Latagliata R, Cannella L, Minotti C, Meloni G, Lo-Coco F (2010) Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica 95(5):853–854. https://doi.org/10.3324/haematol.2009.017962 CrossRefPubMed

Kayser S, Schlenk RF, Platzbecker U (2018) Management of patients with acute promyelocytic leukemia. Leukemia 32(6):1277–1294. https://doi.org/10.1038/s41375-018-0139-4 CrossRefPubMed

Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, Xu F, Wang BS, Mao JH, Shen ZX, Chen SJ, Chen Z (2008) Dissection of mechanisms of Chinese medicinal formula Realgar-indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A 105(12):4826–4831. https://doi.org/10.1073/pnas.0712365105 CrossRefPubMedPubMedCentral

Ma H, Yang J (2015) Insights into the all-trans-retinoic acid and arsenic trioxide combination treatment for acute promyelocytic leukemia: a meta-analysis. Acta Haematol 134(2):101–108. https://doi.org/10.1159/000369242 CrossRefPubMed

Jalili M, Salehzadeh-Yazdi A, Mohammadi S, Yaghmaie M, Ghavamzadeh A, Alimoghaddam K (2017) Meta-analysis of gene expression profiles in acute promyelocytic leukemia reveals involved pathways. Int J Hematol Oncol Stem Cell Res 11(1):1–12PubMedPubMedCentral

Yamamoto Y, Tsuzuki S, Tsuzuki M, Handa K, Inaguma Y, Emi N (2010) BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. Blood 116(20):4274–4283. https://doi.org/10.1182/blood-2010-01-264432 CrossRefPubMed

Abdelrahman M, El-Sayed MA, Hashem A, Abd Allah EF, Alqarawi AA, Burritt DJ, Tran LP (2018) Metabolomics and transcriptomics in legumes under phosphate deficiency in relation to nitrogen fixation by root nodules. Front Plant Sci 9:922. https://doi.org/10.3389/fpls.2018.00922 CrossRefPubMedPubMedCentral

Suhling M, Wolke C, Scharf C, Lendeckel U (2018) Proteomics and transcriptomics in atrial fibrillation. Herzschrittmacherther Elektrophysiol 29(1):70–75. https://doi.org/10.1007/s00399-017-0551-x CrossRefPubMed

10.

Kazan K, Gardiner DM (2018) Transcriptomics of cereal-Fusarium graminearum interactions: what we have learned so far. Mol Plant Pathol 19(3):764–778. https://doi.org/10.1111/mpp.12561 CrossRefPubMed

11.

Iorio F, Rittman T, Ge H, Menden M, Saez-Rodriguez J (2013) Transcriptional data: a new gateway to drug repositioning? Drug Discov Today 18(7–8):350–357. https://doi.org/10.1016/j.drudis.2012.07.014 CrossRefPubMedPubMedCentral

12.

Bredel M, Jacoby E (2004) Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat Rev Genet 5(4):262–275. https://doi.org/10.1038/nrg1317 CrossRefPubMed

13.

Kupershmidt I, Su QJ, Grewal A, Sundaresh S, Halperin I, Flynn J, Shekar M, Wang H, Park J, Cui W, Wall GD, Wisotzkey R, Alag S, Akhtari S, Ronaghi M (2010) Ontology-based meta-analysis of global collections of high-throughput public data. PLoS One 5(9). https://doi.org/10.1371/journal.pone.0013066

14.

Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR (2006) The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science (New York, NY) 313(5795):1929–1935. https://doi.org/10.1126/science.1132939 CrossRef

15.

Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, Jensen LJ, von Mering C (2017) The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 45(D1):D362–d368. https://doi.org/10.1093/nar/gkw937 CrossRefPubMed

16.

Hess F, Estrugo D, Fischer A, Belka C, Cordes N (2007) Integrin-linked kinase interacts with caspase-9 and -8 in an adhesion-dependent manner for promoting radiation-induced apoptosis in human leukemia cells. Oncogene 26(10):1372–1384. https://doi.org/10.1038/sj.onc.1209947 CrossRefPubMed

17.

Ibanez M, Carbonell-Caballero J, Garcia-Alonso L, Such E, Jimenez-Almazan J, Vidal E, Barragan E, Lopez-Pavia M, LLop M, Martin I, Gomez-Segui I, Montesinos P, Sanz MA, Dopazo J, Cervera J (2016) The mutational landscape of acute promyelocytic leukemia reveals an interacting network of co-occurrences and recurrent mutations. PLoS One 11(2):e0148346. https://doi.org/10.1371/journal.pone.0148346 CrossRefPubMedPubMedCentral

18.

Mehdipour P, Santoro F, Botrugno OA, Romanenghi M, Pagliuca C, Matthews GM, Johnstone RW, Minucci S (2017) HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia. Leukemia 31(4):995–997. https://doi.org/10.1038/leu.2017.3 CrossRefPubMed

19.

Chen Z, Chen SJ (1992) RARA and PML genes in acute promyelocytic leukemia. Leuk Lymphoma 8(4–5):253–260. https://doi.org/10.3109/10428199209051004 CrossRefPubMed

20.

Cornic M, Agadir A, Degos L, Chomienne C (1994) Retinoids and differentiation treatment: a strategy for treatment in cancer. Anticancer Res 14(6a):2339–2346PubMed

21.

Such E, Cervera J, Valencia A, Barragan E, Ibanez M, Luna I, Fuster O, Perez-Sirvent ML, Senent L, Sempere A, Martinez J, Martin-Aragones G, Sanz MA (2011) A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia. Blood 117(1):242–245. https://doi.org/10.1182/blood-2010-06-291658 CrossRefPubMed

22.

Reader JC, Meekins JS, Gojo I, Ning Y (2007) A novel NUP98-PHF23 fusion resulting from a cryptic translocation t(11;17)(p15;p13) in acute myeloid leukemia. Leukemia 21(4):842–844. https://doi.org/10.1038/sj.leu.2404579 CrossRefPubMed

23.

Xia Y, Brown L, Yang CY, Tsan JT, Siciliano MJ, Espinosa R 3rd, Le Beau MM, Baer RJ (1991) TAL2, a helix-loop-helix gene activated by the (7;9)(q34;q32) translocation in human T-cell leukemia. Proc Natl Acad Sci U S A 88(24):11416–11420CrossRef

24.

Zhang LJ, Gan YM, Yu L (2015) Occurrence of BCR/ABL fusion gene in a patient with acute promyelocytic leukemia. Med Oncol 32(1):382. https://doi.org/10.1007/s12032-014-0382-0 CrossRefPubMed

25.

Noguchi Y, Okazaki Y, Shimomura D, Yakushijin K, Yamamoto K, Matsuoka H, Minami H, Itoh T, Kawano S, Swaminathan S, Garg S, Madkaikar M, Gupta M, Jijina F, Ghosh K (2014) FLT3 and NPM-1 mutations in a cohort of acute promyelocytic leukemia patients from India. Int J Hematol 20(2):160–165. https://doi.org/10.4103/0971-6866.142884 CrossRef

26.

McCulloch D, Brown C, Iland H (2017) Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. OncoTargets Ther 10:1585–1601. https://doi.org/10.2147/ott.s100513 CrossRef

27.

Bloch DB, Nakajima A, Gulick T, Chiche JD, Orth D, de La Monte SM, Bloch KD (2000) Sp110 localizes to the PML-Sp100 nuclear body and may function as a nuclear hormone receptor transcriptional coactivator. Mol Cell Biol 20(16):6138–6146CrossRef

28.

Santana-Lemos BA, de Lima Lange AP, de Lira Benicio MT, Jose TD, Lucena-Araujo AR, Krause A, Thome CH, Rego EM (2011) The CEBPA gene is down-regulated in acute promyelocytic leukemia and its upstream promoter, but not the core promoter, is highly methylated. Haematologica 96(4):617–620. https://doi.org/10.3324/haematol.2010.028365 CrossRefPubMed

29.

Heo SK, Noh EK, Kim JY, Jegal S, Jeong Y, Cheon J, Koh S, Baek JH, Min YJ, Choi Y, Jo JC (2018) Rhein augments ATRA-induced differentiation of acute promyelocytic leukemia cells. Phytomedicine 49:66–74. https://doi.org/10.1016/j.phymed.2018.06.027 CrossRefPubMed

30.

Abramowitz J, Neuman T, Perlman R, Ben-Yehuda D (2017) Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal acute myeloid leukemia and acute promyelocytic leukemia. BMC Med Genet 10(1):18. https://doi.org/10.1186/s12920-017-0249-2 CrossRef

31.

Furugaki K, Pokorna K, Le Pogam C, Aoki M, Reboul M, Bajzik V, Krief P, Janin A, Noguera ME, West R, Charron D, Chomienne C, Pla M, Moins-Teisserenc H, Padua RA (2010) DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model. Blood 115(3):653–656. https://doi.org/10.1182/blood-2007-08-109009 CrossRefPubMed

32.

Qian X, He J, Zhao Y, Lin M (2016) Inhibition of p38 MAPK phosphorylation is critical for bestatin to enhance ATRA-induced cell differentiation in acute promyelocytic leukemia NB4 cells. Am J Ther 23(3):e680–e689. https://doi.org/10.1097/01.mjt.0000433950.01406.b3 CrossRefPubMed

33.

Dunoyer-Geindre S, Rivier-Cordey AS, Tsopra O, Lecompte T, Kruithof EKO (2017) Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1beta. Ann Hematol 96(6):905–917. https://doi.org/10.1007/s00277-017-2970-5 CrossRefPubMedPubMedCentral

34.

Alex AA, Ganesan S, Palani HK, Balasundaram N, David S, Lakshmi KM, Kulkarni UP, Nisham PN, Korula A, Devasia AJ, Janet NB, Abraham A, Srivastava A, George B, Padua RA, Chomienne C, Balasubramanian P, Mathews V (2018) Arsenic trioxide enhances the NK cell cytotoxicity against acute promyelocytic leukemia while simultaneously inhibiting its bio-genesis. Front Immunol 9:1357. https://doi.org/10.3389/fimmu.2018.01357 CrossRefPubMedPubMedCentral

35.

Lohrmann HP (1984) The problem of permanent bone marrow damage after cytotoxic drug treatment. Oncology 41(3):180–184. https://doi.org/10.1159/000225819 CrossRefPubMed

36.

Koksal AR, Alkim C, Altinkaya E, Bugdaci MS, Ozdogan O, Boga S, Alkim H, Sokmen M (2011) Infliximab- and azathioprine-related severe neutropenia and thrombocytopenia in a case with Crohn’s disease. Turk J Gastroenterol 22(5):537–539CrossRef

37.

Yakar F, Yildiz N, Yakar A, Kilicaslan Z (2013) Isoniazid- and rifampicin-induced thrombocytopenia. Multidiscip Respir Med 8(1):13. https://doi.org/10.1186/2049-6958-8-13 CrossRefPubMedPubMedCentral

38.

Matthews GM, Mehdipour P, Cluse LA, Falkenberg KJ, Wang E, Roth M, Santoro F, Vidacs E, Stanley K, House CM, Rusche JR, Vakoc CR, Zuber J, Minucci S, Johnstone RW (2015) Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. Blood 126(21):2392–2403. https://doi.org/10.1182/blood-2015-03-632984 CrossRefPubMedPubMedCentral

39.

Leung M, Wong K (1997) The combined differentiating effect of retinoic acid and vincristine on acute promyelocytic leukemia. Leuk Res 21(1):81–84CrossRef

40.

Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, von Mering C (2015) STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43(Database issue):D447–D452. https://doi.org/10.1093/nar/gku1003 CrossRefPubMed

Title: Chemogenomics analysis of drug targets for the treatment of acute promyelocytic leukemia
Authors: Si Chen
Xiang Li
Shifan Ma
Xinrui Xing
Xiaobo Wang
Zhenyu Zhu
Publication date: 01-04-2020
Publisher: Springer Berlin Heidelberg
Keyword: Acute Promyelocytic Leukemia
Published in: Annals of Hematology / Issue 4/2020
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-019-03888-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2020

An update to the pathogenesis for monoclonal gammopathy of renal significance

Successful sirolimus treatment of patients with pure red cell aplasia complicated with renal insufficiency

Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report

Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome

Comparison of two different anti-infectious approaches after high-dose chemotherapy and autologous stem cell transplantation for hematologic malignancies in a 12-year period in British Hospital, Uruguay

T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials